Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Change in Receivables (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Change in Receivables for 16 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables fell 120.36% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.3 million, a 244.85% increase, with the full-year FY2024 number at $755000.0, down 91.36% from a year prior.
  • Change in Receivables was -$1.2 million for Q3 2025 at Xtant Medical Holdings, down from $3.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.9 million in Q3 2023 to a low of -$1.2 million in Q3 2025.
  • A 5-year average of $1.0 million and a median of $903000.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: plummeted 215.61% in 2021, then soared 2068.06% in 2025.
  • Xtant Medical Holdings' Change in Receivables stood at $903000.0 in 2021, then increased by 8.42% to $979000.0 in 2022, then surged by 72.52% to $1.7 million in 2023, then crashed by 62.88% to $627000.0 in 2024, then crashed by 296.81% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Change in Receivables are -$1.2 million (Q3 2025), $3.8 million (Q2 2025), and $3.1 million (Q1 2025).